A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
Status:
Completed
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
of single ascending intramuscular doses of MK-5720, and the safety and tolerability of
multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary
study hypothesis is that the administration of MK-5720 is safe and well tolerated.